Next Generation Cell Therapy Articles & Analysis: Older
15 news found
(“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform, today announced the completion of its business combination with Dynamics Special Purpose Corp. ...
Rajangam, who will join the company this July, is an experienced biotechnology executive with an extensive track record of successfully developing cancer therapies across multiple modalities. Senti Bio is developing next-generation cell and gene therapies engineered with gene circuits, which are designed to ...
“Our next-generation cell therapies, powered by our proprietary gene circuit technology, are designed to target multiple disease pathways to overcome the tumor microenvironment and provide enhanced cancer-killing activity. ...
Senti Bio is designing gene circuits to create a new generation of “smarter medicines" to potentially enhance the therapeutic effectiveness of cell and gene therapies against a broad range of diseases that are unaddressable by current standards of care. ...
Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially enhanced capabilities. Gene Circuits, which are created via synthetic biology and encoded as novel and proprietary combinations of DNA sequences, enable cells to sense inputs, compute decisions with biological logic, and respond to disease environments. ...
The results indicate superior tumor killing and persistence of CAR-NK cells as well as optimal activation of other anti-tumor immune cells. ...
A major obstacle in treating solid tumors with cell therapies is overcoming the immunosuppressive tumor microenvironment (TME). ...
(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in the LLS TAP panel discussion entitled “Expanding the Possible with Next ...
” “The collaboration with Century Therapeutics is an important part of our investment strategy in next-generation cell therapies for hematologic and solid tumors,” said Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil., Executive Vice President & President, Research & Early Development, Bristol Myers ...
Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially enhanced capabilities. Gene Circuits, which are created via synthetic biology and encoded as novel and proprietary combinations of DNA sequences, enable cells to sense inputs, compute decisions with biological logic, and respond to disease environments. ...
NEW YORK, December 17, 2021 – Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been added to the ICE Biotechnology Index (NYSE:ICEBIO) following the ...
” Third Quarter 2021 and Subsequent Company Progress Adoptive Cell Therapy Programs ACTengine® IMA203 – On November 13, Dr. ...
” Through this collaboration, Senti Bio will seek to bolster BlueRock’s cell+gene platform by developing gene circuits to precisely control cell differentiation and therapeutic payload expression, in an effort to accelerate BlueRock’s efforts to create next-generation cellular therapies, and ...
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, has announced that President & CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mediterranean to be held virtually April 6-9, 2021. ...
T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties - Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF BERLIN, Germany, August 06, 2020/GlobeNewswire/– T-knife GmbH, a ...